Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

2306 results about "Succinates" patented technology

Derivatives of SUCCINIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a 1,4-carboxy terminated aliphatic structure.

Methods and organisms for the growth-coupled production of succinate

InactiveUS20070111294A1Stable growth-coupled productionFungiBacteriaMicroorganismSuccinic acid
The invention provides a non-naturally occurring microorganism comprising one or more gene disruptions encoding an enzyme associated with growth-coupled production of succinate when an activity of the enzyme is reduced, whereby the one or more gene disruptions confers stable growth-coupled production of succinate onto the non- naturally occurring microorganism. Also provided is a non-naturally occurring microorganism comprising a set of metabolic modifications obligatory coupling succinate production to growth of the microorganism, the set of metabolic modifications comprising disruption of one or more genes selected from the set of genes comprising: (a) adhE, ldhA; (b) adhE, ldhA, acka-pta; (c) pfl, ldhA; (d) pfl, ldhA, adhE; (e) acka-pta, pykF, atpF, sdhA; (f) acka-pta, pykF, ptsG, or (g) acka-pta, pykF, ptsG, adhE, ldhA, or an ortholog thereof, wherein the microorganism exhibits stable growth-coupled production of succinate. Additionally provided is a non-naturally occurring microorganism having the genes encoding the metabolic modification (e) acka-pta, pykF, atpF, sdhA that further includes disruption of at least one gene selected from pyka, atpH, sdhB or dhaKLM; a non-naturally occurring microorganism having the genes encoding the metabolic modification (f) ackA-pta, pykF, ptsG that further includes disruption of at least one gene selected from pykA or dhaKLM, or a non-naturally occurring microorganism having the genes encoding the metabolic modification (g) ackA-pta, pykF, ptsG, adhE, ldhA that further includes disruption of at least one gene selected from pykA or dhaKLM. The disruptions can be complete gene disruptions and the non-naturally occurring organisms can include a variety of prokaryotic or eukaryotic microorganisms. A method of producing a non-naturally occurring microorganism having stable growth-coupled production of succinate also is provided. The method includes: (a) identifying in silico a set of metabolic modifications requiring succinate production during exponential growth, and (b) genetically modifying a microorganism to contain the set of metabolic modifications requiring succinate production.
Owner:GENOMATICA INC

Mixed glue bundle pharmaceutical preparations produced in combination use of multiple surfactant and processes for their preparation

The present invention relates to a mixed micelle medicine preparation and a preparation method, which is prepared by the combination of various kinds of surface acting agents. The mixed micelle consists of the polyethylene glycol-12-hydroxy stearate and the other surface acting agents of one kind or various kinds. The other surface acting agents comprise phospholipid, VE Macrogol succinate, Macrogol-VE-carbonate and Macrogol-VE-succinate. In addition, the mixed micelle also comprises drugs, solvent, a stabilizer with or without other components and a PH conditioner. The amount of the polyethylene glycol-12-hydroxy stearate in the prescription is 4 percentage to 40 percentage, W / V: the amount of the phospholipid is 0 percentage to 30 percentage, W / V: the amount of the activator is 0 percentage to 30 percentage, W / V: the amount of the drug is 0.001 percentage to 10 percentage, W / V: the amount of the solvent is 0 percentage to 90 percentage, W / V. The medicine comprises the hydrophobicity drug and the lip solubility drug, but the medicine is not restricted by the both kinds of drugs. The present invention has the following advantages. Firstly, the preparation has good dilution stability, which can improve the defect in the present preparation and can meet the demanding for clinical drug administration. Secondly, the toxicity is low and the chemical stability is excellent.
Owner:SHENYANG PHARMA UNIVERSITY

Catalyst that can be used in hydrotreatment, comprising metals of groups viii and VIB, and preparation with acetic acid and dialkyl succinate c1-c4

The invention relates to a catalyst usable in hydrotreatment processes, which comprises an alumina-based amorphous support, phosphorus, a C1-C4 dialkyl succinate, acetic acid and a hydro-dehydrogenizing function comprising at least one group VIII element and at least one group VIB element, preferably made up of cobalt and molybdenum, a catalyst whose Raman spectrum comprises the most intense bands characteristic of the Keggin heteropolyanions (974 and / or 990 cm−1), C1-C4 dialkyl succinate and acetic acid (896 cm−1). Preferably, the dialkyl succinate concerned is dimethyl succinate and its main band is at 853 cm−1.The invention also relates to the method of preparing said catalyst, wherein a catalytic precursor comprising the group VIB and group VIII elements, in particular the molybdenum-cobalt pair, and phosphorus, introduced by impregnation, then dried at a temperature below 180° C., is impregnated by the C1-C4 dialkyl succinate, the acetic acid and the phosphorus compound, if the latter has not been entirely introduced beforehand, then, after maturation, dried at a temperature below 180° C. prior to being optionally sulfurized.The invention also relates to the use of this catalyst in any hydrotreatment process.
Owner:TOTAL RAFFINAGE MARKETING +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products